FDA Adverse Event Injury Summary report: N

LIBERTE' MONORAIL CORONARY STENT DELIVERY SYSTEM

MDR report key: 1001536 · Received February 21, 2008

Report

Report Number
2134265-2008-00521
Event Type
Injury
Date Received
February 21, 2008
Date of Event
January 10, 2008
Report Date
February 5, 2008
Manufacturer
BOSTON SCIENTIFIC
Product Code
MAF
PMA / PMN Number
P040016
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
AR
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

THE COMPLAINANT INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVAL; THEREFORE, A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. A REVIEW OF THE BATCH HISTORY, HISTORICAL TRENDING, AND SIMILAR COMPLAINT TRENDING REVIEW FOR THE PRODUCT FAMILY WILL BE CONDUCTED. IF THERE IS ANY FURTHER RELEVANT INFO FROM THAT REVIEW, A SUPPLEMENTAL MEDWATCH WILL BE FILED.

Description of Event or Problem · 1

CLINICAL STUDY. SAME PATIENT AS 2134265-2008-00359. SAME CASE AS 2134265-2008-00520. IT WAS REPORTED THAT DURING 13 MONTH ANGIOGRAPHIC CONTROL, CRITICAL RESTENOSIS WAS DISCOVERED. THE LESION BEING TREATED WAS LOCATED IN THE MID AND DISTAL RIGHT CORONARY ARTERY (MID & DIST RCA). THIS WAS A STAGED PROCEDURE, OCCURRING 2 MONTHS AFTER THE FIRST PORTION WHICH OCCURRED IN 2006. THE PHYSICIAN PLACED 2 LIBERTE' BARE METAL STENTS OF UNKNOWN SIZES IN THE TARGET LESIONS. THIRTEEN MONTHS AFTER THE INDEX PROCEDURE, THE PT EXPERIENCED CRITICAL RESTENOSIS AS DIAGNOSED WITH ANGIOGRAPHIC FOLLOW-UP IN THE RCA. THE PT WAS ASYMPTOMATIC FOLLOW-UP IN THE RCA. THE PT WAS ASYMPTOMATIC WITH NORMAL ACTIVITY. THE PHYSICIAN PLACED A TAXUS LIBERTE' STENT IN EACH RESTENOSED SEGMENT. THE PT WAS DISCHARGED ON ASPIRIN 100 MG/DAY CLOPIDOGREL 75 MG/DAY, RAMIPRIL 1, 25 MG/DAY, CARVEDILOL 6, 25 MG/DAY, SIMVASTATIN 40 MG/DAY, ENOXAPARIN 40 MG SC DAILY. NO ADDITIONAL INFO IS AVAILABLE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 LIBERTE' MONORAIL CORONARY STENT DELIVERY SYSTEM MAF STENT, CORONARY MAF BOSTON SCIENTIFIC

Patients

Seq Age Sex Outcome Treatment
1 71 YR Hospitalization| R